Free Access
Med Sci (Paris)
Volume 34, Novembre 2018
Les Cahiers de Myologie
Page(s) 35 - 38
Section JSFM 2017
Published online 12 November 2018
  1. Kostallari E Baba-Amer Y Alonso-Martin S et al. Pericytes in the myovascular niche promote post-natal myofiber growth and satellite cell quiescence. Development 2015 ; 142 : 1242–1253. [CrossRef] [PubMed] [Google Scholar]
  2. Relaix F Zammit PS Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 2012 ; 139 : 2845–2856. [CrossRef] [PubMed] [Google Scholar]
  3. De Bleecker JL Lundberg IE de Visser M 193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November-2 December 2012, Naarden. The Netherlands. Neuromuscul Disord 2013 ; 23 : 945–951. [CrossRef] [Google Scholar]
  4. Gitiaux C Latroche C Weiss-Gayet M et al. Myogenic progenitor cells exhibit type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis. Arthritis Rheumatol Hoboken NJ 2018 ; 70 : 134–145. [CrossRef] [Google Scholar]
  5. Rigolet M, Hou C, Baba Amer Y, et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. 2018 (soumis pour publication). [Google Scholar]
  6. Aouizerate J De Antonio M Bassez G et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun 2014 ; 2 : 154. [Google Scholar]
  7. Londhe P Davie JK Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator. CIITA. Mol Cell Biol 2011 ; 31 : 2854–2866. [CrossRef] [Google Scholar]
  8. Cheng M Nguyen MH Fantuzzi G et al. Endogenous interferon is required for efficient skeletal muscle regeneration. AJP Cell Physiol 2008 ; 294 : C1183–C1191. [CrossRef] [Google Scholar]
  9. Grzelkowska-Kowalczyk K Wicik Z Majewska A et al. Transcriptional regulation of important cellular processes in skeletal myogenesis through interferon-g. J Interferon Cytokine Res 2015 ; 35 : 89–99. [CrossRef] [PubMed] [Google Scholar]
  10. Higgs BW Zhu W Morehouse C et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014 ; 73 : 256–262. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.